Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
出版年份 2019 全文链接
标题
Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
作者
关键词
-
出版物
Scientific Reports
Volume 9, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-12-03
DOI
10.1038/s41598-019-54804-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)
- (2019) Toshihide Yokoyama et al. LUNG CANCER
- Effects of Pharmacokinetics-related Genetic Polymorphisms on the Side Effect Profile of Afatinib in Patients with Non-Small Cell Lung Cancer
- (2019) Hideki Hayashi et al. LUNG CANCER
- Effect of dose adjustment on the safety and efficacy of afatinib forEGFRmutation-positive lung adenocarcinoma:post hocanalyses of the randomized LUX-Lung 3 and 6 trials
- (2016) J. C.-H. Yang et al. ANNALS OF ONCOLOGY
- Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
- (2016) Sven Wind et al. CLINICAL PHARMACOKINETICS
- Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study
- (2016) Sabrina Wiebe et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
- (2015) Jacques De Grève et al. LUNG CANCER
- Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors
- (2014) Matthias Freiwald et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
- (2014) David Schnell et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours
- (2013) Sven Wind et al. CLINICAL PHARMACOKINETICS
- LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
- (2013) Nobuyuki Katakami et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations
- (2013) Eiki Ichihara et al. LUNG CANCER
- Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?
- (2012) N R Budha et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now